JPH05368B2 - - Google Patents

Info

Publication number: JPH05368B2
Authority: JP; Japan
Prior art keywords: oxypurinol; pharmaceutical composition; tissue; amino acid; composition according
Prior art date: 1986-03-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP62057859A

Other languages

English (en)

Japanese (ja)

Other versions

JPS62230730A (ja

Inventor

Eichi Namu Donarudo

Supekutaa Toomasu

Baagaa Junia Henrii

Jei Furangakisu Kurisuto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wellcome Foundation Ltd

Original Assignee

Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-03-13

Filing date

1987-03-12

Publication date

1993-01-05

1987-03-12 Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd

1987-10-09 Publication of JPS62230730A publication Critical patent/JPS62230730A/ja

1993-01-05 Publication of JPH05368B2 publication Critical patent/JPH05368B2/ja

Status Granted legal-status Critical Current

Links

HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 claims description 33
150000001413 amino acids Chemical group 0.000 claims description 14
230000010410 reperfusion Effects 0.000 claims description 14
230000006378 damage Effects 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 7
210000004369 blood Anatomy 0.000 claims description 7
230000000302 ischemic effect Effects 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
210000005003 heart tissue Anatomy 0.000 claims description 3
229930182817 methionine Natural products 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 3
239000004474 valine Substances 0.000 claims description 3
229920001184 polypeptide Polymers 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims 1
108010079364 N-glycylalanine Proteins 0.000 claims 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims 1
210000001519 tissue Anatomy 0.000 description 22
239000000203 mixture Substances 0.000 description 20
239000000243 solution Substances 0.000 description 12
238000001802 infusion Methods 0.000 description 10
238000000034 method Methods 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108010001014 Plasminogen Activators Proteins 0.000 description 7
102000001938 Plasminogen Activators Human genes 0.000 description 7
229940024606 amino acid Drugs 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
230000017531 blood circulation Effects 0.000 description 7
238000009472 formulation Methods 0.000 description 7
229940127126 plasminogen activator Drugs 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
206010061216 Infarction Diseases 0.000 description 6
208000007536 Thrombosis Diseases 0.000 description 6
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
230000007574 infarction Effects 0.000 description 6
238000002360 preparation method Methods 0.000 description 5
101150074155 DHFR gene Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
108010093894 Xanthine oxidase Proteins 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
230000002861 ventricular Effects 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
102000013566 Plasminogen Human genes 0.000 description 3
108010051456 Plasminogen Proteins 0.000 description 3
102000012479 Serine Proteases Human genes 0.000 description 3
108010022999 Serine Proteases Proteins 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
208000014674 injury Diseases 0.000 description 3
229950006238 nadide Drugs 0.000 description 3
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
239000000047 product Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
229940075420 xanthine Drugs 0.000 description 3
PZJLXGCJHYJOIP-UHFFFAOYSA-N 1h-pyrazole-4,5-dicarboxamide Chemical compound NC(=O)C1=CNN=C1C(N)=O PZJLXGCJHYJOIP-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
108010023197 Streptokinase Proteins 0.000 description 2
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical group [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
102000005773 Xanthine dehydrogenase Human genes 0.000 description 2
108010091383 Xanthine dehydrogenase Proteins 0.000 description 2
102100033220 Xanthine oxidase Human genes 0.000 description 2
-1 alkaline earth metal salts Chemical class 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
208000034158 bleeding Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
230000004087 circulation Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003527 fibrinolytic agent Substances 0.000 description 2
230000003480 fibrinolytic effect Effects 0.000 description 2
230000005484 gravity Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000005240 left ventricle Anatomy 0.000 description 2
239000012931 lyophilized formulation Substances 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000523 sample Substances 0.000 description 2
229960005202 streptokinase Drugs 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
229940116269 uric acid Drugs 0.000 description 2
229960005356 urokinase Drugs 0.000 description 2
230000002792 vascular Effects 0.000 description 2
ZPEZUAAEBBHXBT-WCCKRBBISA-N (2s)-2-amino-3-methylbutanoic acid;2-amino-3-methylbutanoic acid Chemical compound CC(C)C(N)C(O)=O.CC(C)[C@H](N)C(O)=O ZPEZUAAEBBHXBT-WCCKRBBISA-N 0.000 description 1
IKTPUTARUKSCDG-UHFFFAOYSA-N 1h-pyrazole-4,5-dicarboxylic acid Chemical compound OC(=O)C=1C=NNC=1C(O)=O IKTPUTARUKSCDG-UHFFFAOYSA-N 0.000 description 1
BRDIFBARJKLSSY-UHFFFAOYSA-N 2,3,4-triphenyl-2h-tetrazol-2-ium;chloride Chemical compound [Cl-].C1=[NH+]N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 BRDIFBARJKLSSY-UHFFFAOYSA-N 0.000 description 1
DVICWXUADSCSLL-DDEWRDOISA-N Alloxanthin/Tetradehydrozeaxanthin/(Cynthiaxanthin)/(Pectenoxanthin) Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1C#CC(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C#CC1=C(C)C[C@@H](O)CC1(C)C DVICWXUADSCSLL-DDEWRDOISA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
101000981884 Brevibacillus parabrevis Valine racemase [ATP-hydrolyzing] Proteins 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
101150086776 FAM3C gene Proteins 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
235000003332 Ilex aquifolium Nutrition 0.000 description 1
235000002296 Ilex sandwicensis Nutrition 0.000 description 1
235000002294 Ilex volkensiana Nutrition 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
DVICWXUADSCSLL-GUPSQEAKSA-N all-trans-Alloxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C#CC1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C#CC2=C(C)CC(O)CC2(C)C DVICWXUADSCSLL-GUPSQEAKSA-N 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical class OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
UFRRRMXNFIGHPC-CPZJCIGYSA-N alloxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C#CC1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC#CC2=C(C)CC(O)CC2(C)C UFRRRMXNFIGHPC-CPZJCIGYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000047823 human PLAT Human genes 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003601 intercostal effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000155 melt Substances 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
238000001665 trituration Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP62057859A 1986-03-13 1987-03-12 新規な医薬組成物 Granted JPS62230730A (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB8606283		1986-03-13
GB868606283A GB8606283D0 (en)	1986-03-13	1986-03-13	Cell protection
GB8623835		1986-10-03
GB8701976		1987-01-29

Publications (2)

Publication Number	Publication Date
JPS62230730A JPS62230730A (ja)	1987-10-09
JPH05368B2 true JPH05368B2 (pt)	1993-01-05

Family

ID=10594577

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP62057859A Granted JPS62230730A (ja)	1986-03-13	1987-03-12	新規な医薬組成物
JP5869987A Pending JPS62230725A (ja)	1986-03-13	1987-03-13	細胞防護剤

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP5869987A Pending JPS62230725A (ja)	1986-03-13	1987-03-13	細胞防護剤

Country Status (3)

Country	Link
JP (2)	JPS62230730A (pt)
GB (1)	GB8606283D0 (pt)
ZA (1)	ZA871814B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH05501563A (ja) *	1989-11-18	1993-03-25	シエーリング・アグロケミカルズ・リミテツド	プロペン酸誘導体の製造

1986
- 1986-03-13 GB GB868606283A patent/GB8606283D0/en active Pending
1987
- 1987-03-12 ZA ZA871814A patent/ZA871814B/xx unknown
- 1987-03-12 JP JP62057859A patent/JPS62230730A/ja active Granted
- 1987-03-13 JP JP5869987A patent/JPS62230725A/ja active Pending

Also Published As

Publication number	Publication date
JPS62230730A (ja)	1987-10-09
JPS62230725A (ja)	1987-10-09
GB8606283D0 (en)	1986-04-16
ZA871814B (en)	1988-10-26

Publication	Publication Date	Title
CA2171266C (en)	2010-05-18	Stable transglutaminase preparations and processes for producing them
AU600724B2 (en)	1990-08-23	Novel combination
US5084273A (en)	1992-01-28	Composition of anticoagulants
JPH0759517B2 (ja)	1995-06-28	組織プラスミノーゲン活性化因子含有医薬組成物
EP0123304A2 (en)	1984-10-31	A method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same
US5202117A (en)	1993-04-13	Method of treating thrombi with g-csf
JPH0714886B2 (ja)	1995-02-22	安定化されたヒト組織プラスミノゲン活性化因子組成物
DK167738B1 (da)	1993-12-13	Fremgangsmaade til fremstilling af en oploesning med hoej specifik rumfangsaktivitet af et protein med vaevs-plasminogenaktivator(t-pa)-aktivitet, oploesning der indeholder protein med t-pa-aktivitet, og anvendelsen af oploesningen inden for human- og veterinaermedicinen
CA1297009C (en)	1992-03-10	Use of t-pa for the inhibition of damage to jeopardized tissue during reperfusion in a mammal
JPH0273022A (ja)	1990-03-13	組織プラスミノーゲン活性化因子を用いた薬学的製剤
US4839169A (en)	1989-06-13	Synergistic combination of t-PA and prostacyclin
EP0304311A1 (en)	1989-02-22	Complex of polyethylene glycol and tissue plasminogen activator
AU598239B2 (en)	1990-06-21	The application of tissue plasminogen activator and oxypurinol in dissolving blood clots and in preventing damage to ischaemic tissue during reperfusion
JPH05368B2 (pt)	1993-01-05
JPH01240186A (ja)	1989-09-25	フィブリン特異性２本鎖プラスミノーゲンアクチベーター
CA2475738A1 (en)	2003-09-18	Activated protein c formulations
US5342616A (en)	1994-08-30	Method of administering tissue plasminogen activator
JPS6226233A (ja)	1987-02-04	組織プラスミノ−ゲン活性化因子含有医薬組成物
US20020151481A1 (en)	2002-10-17	MMP-2 propeptide for use as antiangiogenic or antitumor agent
EP0352897A1 (en)	1990-01-31	TPA-containing medicaments
US20040242480A1 (en)	2004-12-02	Method for treating coumarin-induced hemorrhage
Robison et al.	1986	Activators of Plasminogen
JPH049334A (ja)	1992-01-14	線溶活性増強剤